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A B S T R A C T
In the last years, the increase in antimicrobial resistance, together with a lack of new drugs for the treatment of
bacterial infections resistant to classical antibiotics are of growing concern. Moreover, some of current therapies
induce severe side effects and are often difficult to administer. In 2012 the FDA approved the use of bedaquiline,
as the first new very effective drug against TB in the last 40 years. Despite its effectiveness, unfortunately be-
daquiline side effects can be so dangerous that at present it is to be prescribed only when no other treatment
options are available. The development of effective and safe nanotechnology-based methods can be particularly
relevant to increase antimicrobial concentration at the site of infection, to reduce doses in the general circu-
lation, which in turn reduces adverse effects. In this work bedaquiline was encapsulated in two types of na-
nocarriers, lipid nanoparticles and chitosan-based nanocapsules with high encapsulation efficiency and drug
loading values. The efficacy of the drug-encapsulating nanocarriers has been demonstrated in vitro against
Mycobacterium tuberculosis, together with the excellent compatibility of both carriers with animal cells. The
obtained results open the way for further studies on multi-drug resistant strains of M. tuberculosis and for in vivo
studies of the optimized nanocarriers. The promising behaviour of drug-loaded nanocarriers will hopefully lead
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to a reduction of the administered doses of a quite dangerous drug as bedaquiline, tuning its biodistribution and
so decreasing its adverse effects, finally allowing its use in a higher number of patients.
1. Introduction
Novel drug delivery systems based on nanocarriers are a promising
strategy to overcome current therapeutic limitations thanks to nano-
materials unique physicochemical properties. These include their small
size, which allows them to reach the cellular level, their high surface to
volume ratio, which increases interactions with target cells and their
ability to be structurally and functionally modified to control their
biodistribution. In addition, nanocarriers allow the improvement of
aqueous solubility of poorly soluble drugs, the drug protection in order
to avoid its degradation before reaching its target, its selective transport
to the sites of infection and the controlled release of the medication to
decrease the frequency of administration [1].
Many studies have been carried out for different anti-TB drugs,
showing the success and usefulness of this technology to improve the
treatment of tuberculosis [2].
The increase in antimicrobial resistance observed in last years is of
growing concern worldwide and only thirteen new antibacterial agents
were approved by the Food and Drug Administration (FDA) between
1999 and 2011 [3]. Mycobacterium tuberculosis (TB) have developed a
high level of drug resistance to antimicrobial drugs. Multidrug resistant
TB (MDR-TB) and extensively drug-resistant TB strains (XDR-TB, a form
of MDR-TB with additional resistance to any of the fluoroquinolones
and to at least one of three injectable second-line) have been identified
in 105 countries worldwide, and they are making increasingly difficult
to successfully treat tuberculosis. Drugs available for the treatment of
bacterial infections resistant to antimicrobial drugs are very limited,
induce severe side effects and/or are difficult to administer, so they
could require parenteral injection [4]. Moreover the high costs of these
treatments and their low success rates should be taken into account [5].
Bedaquiline, a diarylquinoline antimycobacterial drug, the first FDA
approved anti-TB drug in four decades, is a very effective drug, none-
theless it shows serious side effects including induction of life-threa-
tening cardiac arrhythmias [5]. Therefore, this drug is to be prescribed
only when no other treatment options are available [4,6].
The development of effective and safe nanotechnology-based
methods would be particularly relevant to improve the safety of this
drug for the treatment of drug-resistant infections. In fact, the use of a
carrier can increase the local concentration of the drug at the site of
infection, enabling lower doses in the general circulation, which in turn
reduces the adverse effects.
Nanoemulsion-based nanocapsules present a lipidic core highly
suitable for the encapsulation of a very hydrophobic molecule such as
bedaquiline. For this reason, two bedaquiline-loaded nanocarriers have
been developed in this work, consisting in a polymeric shell that sur-
rounds a liquid or solid lipidic core where the drug is confined [7]. They
are nanoemulsion-based chitosan nanocapsules (CS-NC), consisting in
an oily core with a nanogel polysaccharidic shell grafted or not with
polyethylene glycol molecules following a method previously described
in literature by the same authors [8], and lipid nanoparticles (LNPs),
made of a lipid core of long chains triglycerides and surrounded by a
surfactant shell made of a polyethylene glycol based surfactant, phos-
pholipids [9] and eventually cationic lipids in order to confer them a
cationic character [10]. In both cases the polymeric coating has been
used for nanocapsule stabilization [11].
In view of a possible finding of the optimal delivery system for
bedaquiline, the two carriers have been designed for future, different
administration route, being chitosan-based nanomaterials more suitable
for nebulization and lipid nanoparticles very desirable for intravenous
injection.
In the case of chitosan nanocapsules, bedaquiline has been en-
capsulated in the lipidic core and nanoemulsion was stabilized through
chitosan coating by ionotropic gelation process. The same chitosan-
based nanocapsules have been further grafted with a polyethylene
glycol (PEG) layer to improve their colloidal stability in biologically
interesting media. Among the high number of biopolymers used in drug
delivery applications (alginate, hyaluronic acid, pectine, albumin, fi-
broin, etc.) [12,13], chitosan is widely used in nanomedicine because of
the excellent biocompatibility and safety of its degradation products
[14]. Chitosan has been chosen as nanoemulsion stabilizer since it is
very rich in amino groups, which makes it useful to favour interaction
of nanocarrier and respiratory tract mucose. Mucoadhesive properties
of chitosan are especially important for aerosol administration for
pulmonary infections [15,16].
LNPs have been chosen as promising nanocarriers for this work
because they gather several advantages for intravenous administration.
They are composed of molecules generally regarded as safe, display no
cellular toxicity and present long term circulation time due to their high
colloidal stability and to the furtivity provided by the PEG shell
[17,18]. LNPs with two different surface charges were studied, particles
displaying a slightly negative surface charge (hereafter referred as LNPs
(−)), due to the presence of zwitterionic lecithin molecules, and ca-
tionic ones (LNPs(+)), containing DOTAP, a molecule with a qua-
ternary ammonium polar head group. Both types of LNPs exhibited a
PEG-rich outer shell, which is known to be a good strategy for drug
delivery in the field of nanomedical therapy [19].
The encapsulation of bedaquiline has been optimized in the case of
both carriers, upon quantification of drug loading and encapsulation
efficiency. The resulting bedaquiline-loaded nanocapsules have been
also characterized in terms of their physicochemical properties, since
the knowledge of such characteristics is fundamental for the prediction
and control of the interaction of nanomaterials with biological media
and their toxicity [20]. Finally, chitosan nanocapsules and lipid nano-
particles have been compared in terms of their behaviour in biological
systems. In particular, their in vitro antibacterial efficacy towards M.
tuberculosis and their cytotoxicity in human cells have been established,
prior to more in depth studies on multi-drug resistant TB strains and in
vivo infected models.
2. Materials and methods
2.1. Materials
Tween® 20 and absolute EtOH, were purchased from Panreac
Química S.L.U (Barcelona, Spain). Span® 85 (sorbitanetrioleate), oleic
acid and chitosan (medium molecular weight) were purchased from
Sigma-Aldrich Pte. Ltd. (Singapore). Bedaquiline was obtained from
AURUM Pharmatech LLC (Franklin Park, NJ, USA). Bis(sulfosuccini-
midyl) suberate (BS3) was purchased from Pierce Biotechnology Inc.
(Rockford, IL, USA) and α-methoxy-ω-amino poly(ethylene glycol)
(PEG-MW 5000 Dalton) from IRIS Biotech GmbH (Marktredwitz,
Germany). Myrj™ S40 (PEG 40 stearate, 1980 Da) and Super Refined
Soybean Oil were obtained from Croda Uniquema (Chocques, France).
Suppocire NB™ was purchased from Gattefosse S.A. (Saint-Priest,
France). Lipoid® S75-3 (soybean lecithin at 69% of phosphatidylcho-
line) and hydrogenated S75 were provided by Lipoid GmbH
(Ludwigshafen, Germany). All the products were pharmaceutical grade
and used as received. DOTAP (1,2-dioleoyl-3-trimethylammonium-
propane (chloride salt)) was purchased from Avanti® Polar Lipids, Inc.
(Alabaster, Alabama, USA). The fluorophore DiI (Molecular Probes™ Dil
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Stain, D282) was purchased from ThermoFisher Scientific (Illkirch,
France).
Water (double processed tissue culture, endotoxin-free) used in all
nanocapsule synthesis was from Sigma-Aldrich.
Plasma sample from healthy donor (Etablissement Français du Sang
(EFS), Grenoble, FRANCE) collected by apheresis was used. According
to the ethical and legal standards of our blood supplier (EFS), informed
consent was given by blood donors. Blood usage was allowed by Health
Department of Research Ministry as described in the delivered French
directive #DC-2008-334. The plasma pocket was delivered frozen and
aliquoted in separated tubes kept at −20 °C for storage until use.
Bacterial strains used were Mycobacterium tuberculosis reference
strain H37Rv [21] and Mycobacterium bovis BCG expressing the reporter
Green Fluorescent Protein (GFP), both available at Mycobacterial Ge-
netics Group Laboratory (University of Zaragoza). M. tuberculosis cul-
tures were maintained in a BSL-3 laboratory.
Difco™ Middlebrook 7H9 broth and BBLTM Middlebrook ADC
Enrichment were purchased from BD (Becton, Dickinson and Company,
Franklin Lakes, NJ, USA). Glycerol and Tween® 80 were purchased
from Scharlau. Resazurin sodium salt was from Sigma.
Cell lines THP-1 were and HepG2 were obtained from the ECACC:
(cat. N° 88,081,201 and 85,011,430 respectively). Cell line A549 was
available for this work at the University of Zaragoza.
Cell culture media, Roswell Park Memorial Institute medium (RPMI)
and Dulbecco's Modified Eagle Medium (DMEM), used for cytotoxicity
assays, cell culture maintenance and release profile assays, were ob-
tained from Lonza (Basel, Switzerland). The Fetal Bovine Serum was
from GIBCO. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenylte-
trazoliumbromid) and Neutral Red were obtained from Sigma-Aldrich,
as well as Phorbol 12-myristate 13-acetate (PMA).
Millipore Biomax 300 kDa Ultrafiltration Discs and Millex syringe-
driven filter unit (PVDF and cellulose ones) with a pore size of 0.22 µm
and Isopore Membrane Filters, with a pore size of 0.1 µm (VCTP), were
purchased from Merck Millipore. Cellulose membranes used for lipid
nanoparticles purification by dialysis at room temperature for 24 h in
order to remove non-incorporated bedaquiline or any other ingredients
(Regenerated cellulose, MWCO 12–14 kDa, ZelluTrans) were purchased
from ROTH (Roth Sochiel E.U.R.L., Lauterbourg, France).
2.2. Synthesis of bedaquiline-loaded nanocarriers
The general procedure for the obtaining of nanoemulsion-based
chitosan nanocapsules (CS-NC) has been previously reported in De
Matteis et al. 2016 [8]. To encapsulate bedaquiline in nanocapsules,
different amounts of drug were tested. 2, 3.5, 5, 10 or 25mg be-
daquiline were mixed with 100 μL absolute ethanol and 40mg oleic
acid. This solution was then incorporated to an organic solution con-
taining 8.6 mg Span® 85 in 4 μL absolute ethanol. The organic phase
was then added drop by drop to an aqueous one containing 13.6mg
Tween® 20 dissolved in 8mL water under magnetic stirring during
15min for the formation of the nanoemulsion core. In the next step,
0.5 mL of a 5mg/mL chitosan solution in acetic acid 1% (v/v) were
added for the preliminary interaction of the polymer chains with na-
noemulsion cores. Again, the mixture was left under stirring during
15min. Finally, the chitosan-coated nanoemulsion was added to 15mL
of 50mM Na2SO4 under gentle stirring to obtain the final polymeric
hydrogel shell. The excess of Na2SO4 was removed by ultracentrifuga-
tion (69,673 G, 30min, 10 °C), nanocapsules were washed with 10mL
of water, they were centrifugated again and resuspended in water. The
concentration of the nanocapsules in water suspension was obtained by
measuring the weight of a sample after freeze-drying.
For the grafting of chitosan nanocapsules with PEG5000, 20mg of
nanocapsules at a concentration of 2mg/mL in borate buffer 10mM pH
8.3 were put in contact with an amount of 50 nmol/mgNC of bis(sul-
fosuccinimidyl) suberate (BS3) and kept under stirring for 30min. A 1.5
excess of α-methoxy-ω-amino poly (ethylene glycol) (MeO-PEG-NH2)
was added and, after 2 h of the reaction at 40 °C, 20mL of 10mM Tris-
HCl buffer pH 8.0 were added to quench BS3 that eventually did not
react with PEG. Grafted nanocapsules were filtered and washed with
fresh water using an Amicon Ultrafiltration unit equipped with
Millipore Biomax 300 kDa Ultrafiltration Discs.
Lipid nanoparticles (LNP) were prepared by blending lipid and
aqueous phases using ultrasonic process to provide stable nanodroplets.
After homogenization at 55 °C, both phases are crudely mixed and so-
nication cycles are performed at 55 °C during 5min. Non-encapsulated
components are separated from Lipid Nanoparticles (LNPs) by dialysis
with PBS, changing twice the equilibrating PBS buffer (with a volume
equals 200× the LNP dispersion volume) and during 24 h. Prior to
characterization, LNPs dispersions are filtered through a 0.22 µm cel-
lulose membrane.
For LNPs(−), the lipophilic excipients, wax, oil and soya lecithin
made up the oily phase whereas the hydrophilic PEG surfactant,
MyrjS40 is solubilized in PBS as aqueous phase. By selecting the sui-
table weight ratios of core/shell excipients, 80 nm-diameter of LNPs(−)
were manufactured in 2.8 mL-volume batches at 72mg/mL of LNPs.
The lecithin/PEG surfactant weight ratio was of 0.17 and the surfac-
tant/core weight ratio is of 0.85. For cationic LNPs, an additional ca-
tionic surfactant, DOTAP, was added as a lipophilic excipient. The le-
cithin/PEG surfactant weight ratio was of 0.051 and surfactant/core
weight ratio was 0.67. Two different weight ratios between oil and wax,
1/3 and 3, were tested for both LNPs.
Details about the weight percentage of the different components in
anionic and cationic LNPs are reported in Fig. S3 in the Supplementary
Information.
In both cases, the drug was incorporated in the lipid phase by
mixing appropriate amount of bedaquiline stock solution (10mg/mL in
dichloromethane), the solvent being completely evaporated at 55 °C
under Argon flow.
2.3. Determination of bedaquiline encapsulation efficiency and drug loading
Encapsulation efficiency (EE) was intended here as the percentage
of encapsulated drug over the amount added initially to the preparation
of nanocarriers. Drug loading (DL) is intended as the percentage of
encapsulated drug per weight of carrier.
In the case of CS-NCs, to calculate the amount of encapsulated be-
daquiline, 1.5mg of bedaquiline-loaded nanocapsules were mixed with
900 μL methanol and sonicated for 30min, in order to obtain the
complete extraction of the encapsulated drug. This solution was then
filtered using a nylon syringe filter (0.2 μm pores) to eliminate the
chitosan fragments eventually present and the absorbance at 333 nm
was measured using a Varian Cary 50 UV/Vis spectrophotometer after
carrying out a calibration curve of the compound in methanol. The
encapsulated drug amount was also measured after extraction with
dichloromethane from freeze-dried chitosan nanocapsules analysed
with spectrophotometric analysis as previously described using a cali-
bration curve in the same solvent.
Extracted bedaquiline was analysed also by HPLC method in a
Waters 2695 HPLC system equipped with a Waters 2995 PDA detector
and a HILIC column (HALO HILIC 4.6×100mm, 2.7 μm). Samples
were injected (10 μL) and eluted at 30 °C and 0.5mL/min with an iso-
cratic mixture of acetonitrile:water containing 0.2% formic acid
(60:40). Sample quantification was carried out measuring the absor-
bance at 240 nm, by means of a seven-point absolute calibration ran-
ging from 1 to 110 ppm. The method was linear all over the measured
range (r2= 0.9991).
For LNPs, EE is first determined after final dialysis step of the pre-
paration process. An additional method was necessary to be able to
establish drug release profiles in different media as no simple method
like centrifugation or filtration is available to separate LNPs from su-
pernatant. To this purpose, two additional methods have been used for
EE determination and the most appropriate one was chosen for drug
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release profiles. To determine the EE of bedaquiline in LNPs, the drug
concentration in the purified dispersion, after intense dialysis, was
measured by destabilization of LNPs in hydro-organic medium leading
to liquid extraction of bedaquiline in solvent. Bedaquiline-loaded LNPs
were diluted to 1:4 with acetonitrile, then vortexed to destroy the LNPs
and release bedaquiline. A centrifugation of samples was then per-
formed at 13,000 G for 10min. The supernatant was gently withdrawn
and transferred in convenient vial for analysis.
To be able to determine EE with a method alternative to dialysis
purification, an aliquot of the dispersion was purified by SEC or by SPE
[22]. The purified LNPs are then destabilized with the same method
used for EE determination. For SEC purification, 200 µL sample of LNP
dispersion obtained after dialysis, at a concentration comprised be-
tween 15mg/mL and 40mg/mL, was deposited gently on the top of
Superdex 200 gel filtration media packed (15 cm length) in a 15mm
inner diameter glass column (Kimble Chase Flex Column). Continuous
flow of PBS at 0.7mL/min was applied and successive fractions of
500 µL were collected in separate tubes. Optical absorbance at 315 nm
of all fractions was measured in order to identify LNPs containing
fractions. SPE was performed by using a SPE Waters Extraction mani-
fold (20-position, 16× 75mm tubes) connected to a vacuum pump
(KnF, Germany). The SPE-cartridges Oasis® HLB (6mL, 150mg, 80 Å
pore size, 60 µm particle size) composed of N-vinylpyrrolidone and
divinylbenzene polymers were also provided by Waters. In preliminary
step, SPE-cartridges were conditioned by using 4mL of acetonitrile and
equilibrated with 4mL of PBS. After loading 1mL of nanoparticles
sample, the non-adsorbed components were recovered after rinsing the
column by adding 3mL of PBS in a first fraction (F1), this fraction
containing hydrophilic LNP. The free or shell-adsorbed bedaquiline was
eluted in a second fraction (F2) by using 4mL of acetonitrile. All steps
were processed at 5 in Hg. Fractions F1 and F2 were both collected into
5mL-volumetric flasks and diluted to adjust volume to 5mL with PBS
and acetonitrile, respectively. Bedaquiline was then extracted in or-
ganic solvent from F1 fraction as described for EE determination.
Quantification of the drug has been performed by HPLC-UV with a
HPLC Waters Alliance 2695 Separation module and a Waters 2487 UV
detector equipped with a reversed phase SunFire C18. Elution was
performed using a mobile phase composed of acetonitrile (ACN) and
trifluoroacetic acid (TFA) in water at 0.1% with a linear gradient. The
operating temperature was 25 °C and the flow rate was 0.8 mL/min.
Bedaquiline compound was eluted at a retention time of 7.8min using a
linear gradient mode from 50:50 TFA:ACN to 70:30 ACN:TFA with an
injection volume of 20 µL and the UV detection was recorded at
230 nm. Standard curves with pure bedaquiline at 1, 2.5, 5, 7.5 and
10 µg/mL were performed for drug content determination in samples.
The method was linear all over the measured range (r2= 0.9999).
In the case of both carriers, to determine the long-term stability of
drug loading, the previously described method was used to measure
loading after six-month storage period in liquid suspension.
2.4. Characterization of bedaquiline-loaded nanocarriers
CS-NC: Dynamic Light Scattering (DLS) analysis has been carried
out to obtain hydrodynamic diameter and polydispersity index (PDI) of
nanocapsules using a Brookhaven 90Plus DLS instrument, by means of
the Photo-Correlation Spectroscopy (PCS) technique. All measurements
have been carried out in water at the concentration of 0.05mg/mL at
25 °C.
Electrophoretic mobility (ζ potential) of nanoparticles has been
determined by measuring the surface potential of a 0.01mg/mL na-
noparticle suspension in 1mM KCl at 25 °C with a Plus Particle Size
Analyzer (Brookhaven Instruments Corporation).
For the LNPs, the hydrodynamic diameter, polydispersity index and
ζ potential of the lipid nanoparticles were measured with a Zeta Sizer
Nano instrument (NanoZS, Malvern). The hydrodynamic diameter and
PDI were measured with a 0.6 mg/mL LNP dispersion in PBS at 25 °C. ζ
Potential was measured with a 0.4 mg/mL LNP dispersion in 1mM
NaCl, at pH 7.4 and at 25 °C.
2.5. Release study
CS-NC bedaquiline-loaded nanocapsules were mixed with the
proper medium at a concentration of 1.5mg/mL nanocapsules and in-
cubated at 37 °C. Samples were analysed after 1, 2, 3 and 7 days and
bedaquiline retained was extracted from nanocapsules to be measured.
Each solution was passed through a PVDF syringe filter (0.2 µm pores)
to separate the nanocapsules (retained in the filter) from the medium.
Then, 900 μL of methanol were passed through the filter to extract
bedaquiline still encapsulated. The concentration of bedaquiline in
methanol was measured by spectrophotometric analysis at 333 nm and
the amount of released drug was obtained by difference with the initial
amount.
LNPs were prepared in each medium at a concentration of 6.7mg/
mL of nanoparticles, corresponding to 200 µg/mL of bedaquiline and
incubated at 37 °C, with a 350 rpm stirring. After defined periods, an
aliquot of the dispersion was collected for SPE purification and EE
determination. The drug release percentage at time t is defined by EE
(t)-EE(t0).
2.6. In vitro antimicrobial activity assessment
Mycobacterium tuberculosis (reference strain, H37Rv) cultures were
routinely grown at 37 °C in Middlebrook 7H9 medium supplemented
with 10% ADC and 0.05% Tween® 80. Mycobacterium bovis BCG ex-
pressing GFP reporter was maintained in Middlebrook 7H9 medium
supplemented with 10% ADC and 0.05% Tween® 80 with 50 μg/mL
hygromycin.
The Minimum Inhibitory Concentration (MIC) was determined
using the Resazurin Microtiter Assay Plate (REMA) [23]. In 96-well
plates, a range of concentrations of the free bedaquiline or bedaquiline-
loaded nanoparticle were added in 100 µL of Middlebrook 7H9 medium
supplemented with 10% ADC and 0.5% glycerol in a series of twofold
dilutions. Empty nanoparticles were assayed as a control. In this case,
the range of final concentrations for bedaquiline spanned from 1 to
0.008 µg/mL. Bacteria were inoculated by adding 100 µL of a suspen-
sion of 105 cfu/mL, as estimated by optical density and prepared from a
culture in exponential growth phase. After 6 days of incubation at 37 °C,
30 µL of resazurin (0.01% w/v) was added to each well, incubated 48 h
at 37 °C, and assessed for colour change. A change from blue to pink
indicates bacterial growth. The MIC is defined as the lowest drug
concentration that prevents this colour change.
2.7. Scanning Electron Microscopy (SEM) analysis
M. tuberculosis H37Rv cultures were grown for 48 h in the presence
of the BQ-loaded nanocarriers, collected by centrifugation, washed
once, resuspended in fixative solution (2.5% glutaraldehyde in PBS
0.1M) and kept for a minimum of 24 h at room temperature. The
fixative solution was subsequently removed and the bacteria were
washed three times with PBS 0.1M and filtered through a membrane
with a pore size of 0.1 µm.
Filters with the bacteria and the nanocarriers were progressively
dehydrated by immersion in a graded series of ethanol (50–100%). SEM
observations were performed using a field emission SEM Inspect F50
(FEI).
2.8. Confocal Microscopy analysis
M. bovis BCG expressing GFP was incubated at 37 °C in the dark for
72 h with LNPs(−) labelled with the DiL fluorophore at a concentration
of 200 µg/mL. It was then washed once to remove the culture medium,
and fixed with paraformaldehyde 4%. The bacteria were washed twice
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with PBS to remove the fixative agent, and resuspended in water. One
drop of the suspension was placed over the slide, air dried and mounted
with moviol before visualization with the confocal microscope Zeiss
LSM 880 Axio Observer, using an objective 63X/1.4 Oil DIC M27.
2.9. Cytotoxicity assays
Cell lines used in cytotoxicity studies were A549 (lung epithelial
human cells), HepG2 (liver epithelial human cells) and THP1 (human
monocytes from peripheral blood). A549 and HepG2 cells were cul-
tured in T25 vented flasks with DMEM supplemented with 10% fetal
bovine serum, penicillin and streptomycin, incubated at 37 °C/5% CO2.
For the assays they were seeded at a cell density of 104 cell/mL for
A549, and 2.5×104 cell/mL for HepG2. THP-1 cells were cultured in
T25 vented flasks with RPMI-1640 supplemented with 10% fetal bovine
serum, penicillin and streptomycin. For the assays, cells were seeded at
a density of 5×104 cell/mL, and they differentiated into adherent
macrophage-like cells by incubating with PMA at 5 ng/mL for 48 h at
37 °C/5% CO2 [24]. After this period, the medium was changed to RPMI
without PMA for 24 h more before they were exposed to the nano-
carriers [24].
For the MTT viability assay, cells were seeded into a 96-well plate
and maintained in culture for 24 h at 37 °C/5% CO2 to form a semi-
confluent monolayer. They were then exposed to the nanocarriers using
for this purpose DMEM or RPMI medium without phenol red, to avoid
interference with the results. All nanocarriers were tested at 8 different
concentrations prepared as twofold serial dilutions. The range of final
concentrations tested was from 1mg/mL to 7.81 µg/mL. After 24 h of
exposure, the culture medium was removed and 50 μL of 1mg/mL MTT
was added to each well and incubated for 2 h at 37 °C/5% CO2. After
this incubation, supernatant was removed and the formed formazan
crystals were solubilized in isopropanol. The colour intensity of the
dissolved formazan is determined by photometric measurements at
570 nm and the percentage of viable cells was obtained by correlation
to the intensity of the untreated control (100% viability).
For Neutral Red Uptake (NRU) assay, cells were seeded into a 96-
well plate and maintained during 24 h at 37 °C/5% CO2 to form a semi-
confluent monolayer. They were then exposed to the nanocarriers using
for this purpose DMEM or RPMI without phenol red, to avoid inter-
ference with the results. All nanocarriers were tested at 8 different
concentrations prepared as twofold serial dilutions. The range of final
concentrations tested was from 1mg/mL to 7.81 µg/mL. After 24 h
exposure, the culture medium was removed and 100 μL of 0.005%
neutral red solution were added to each well and further incubated at
37 °C/5% CO2 for 3 h. The plates were then washed with PBS and the
dye was extracted with ethanol/acetic acid solution before reading
fluorescence of each well (530/645 nm). The number of viable cells was
obtained by correlation to the intensity of the untreated control (100%
viability) [25].
3. Results and discussion
3.1. Nanocarriers synthesis
Due to the lipophilic character of bedaquiline, the lipidic core of
both LNPs, made of vegetable oil and wax, and of CS-NC, based on non-
ionic surfactant/oleic acid micelles, have been found to be highly sui-
table for the encapsulation of this drug.
In this study the synthesis and characterization of the two kinds of
nanocarriers is reported, from both a physicochemical and biological
Scheme 1. Synthesis processes and schematic representation of the obtained nanocarriers used for bedaquiline encapsulation: CS-NCs (A) and LNPs (B).
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point of view, with the final aim of proposing them as candidates for
future in vivo administration in the treatment of MDR-TB either by
aerosol/nebulization or intravenous injection.
Since nanocapsules are intended as drug nanocontainers, the effi-
ciency of drug encapsulation (EE, percentage of the encapsulated drug
over the amount initially added) and the final drug loading (DL, per-
centage of the encapsulated drug per weight of obtained material) are
important parameters to be optimized in view of biomedical application
of the developed drug carriers. The optimization has been carried out
with both kinds of nanocarriers. A description of the synthesis process
and composition of bedaquiline-loaded nanocarriers is reported in
Scheme 1.
3.1.1. Chitosan nanocapsules
In the case of CS-NCs the encapsulation of bedaquiline required a
proper modification of the procedure already reported in literature [8]
for the addition of bedaquiline to the organic phase of the synthesis
mixture before obtaining the nanoemulsion suspension. The organic
solution, containing the drug as well as the surfactant (Span® 85) and
the oil (oleic acid), is added to an aqueous solution of Tween® 20 and
nanoemulsion is spontaneously formed. At this step bedaquiline was
included in the nanoemulsion core taking advantage of its hydrophobic
nature. Finally the nanoemulsion was put in contact with the poly-
saccharide and this mixture was added to a sodium sulfate solution for
the hydrogel formation. The whole process is schematically described in
Scheme 1A. The grafting of the surface with aminated PEG5000 was
carried out using BS3 as homobifunctional crosslinker and following a
method already optimized in the case of empty nanocapsules [8].
Surface grafting offers the possibility to modify the behaviour of the
nanocarrier in different media and depending on the desired function.
Generally speaking, the modification of nanoparticles surface can be
done to accomplish different objectives: i) to specifically recognize
target tissue or cells, ii) to avoid the adsorption of serum proteins or the
recognition by macrophages, and iii) to avoid aggregation in physio-
logical medium [19,26]. The second and third objectives of the grafting
are usually carried out by the attachment of hydrophilic molecules,
such as polyethylene glycol, to coat the nanocarrier surface and even-
tually tune its properties. In this case, a surface grafting with PEG
molecules of bedaquiline-loaded nanocapsules was performed to de-
crease their aggregation in culture medium and to study how such
modification of their surface could affect cytotoxicity in human cells
and their in vitro antimicrobial efficacy against M. tuberculosis.
To avoid eventual inter-particle crosslinking mediated by BS3 be-
tween amino groups on the surfaces, and so aggregation effects of the
colloidal suspension of chitosan nanocapsules, the minimum amount of
BS3 crosslinker was used to graft nanocapsule surface. 50 nmol BS3/mg
was found to be the optimal amount of crosslinker to allow the linking
of PEG without any aggregation of the nanocarrier. After synthesis and
grafting of nanocapsules, the encapsulated bedaquiline has been
quantified using a method based on the extraction of the drug in or-
ganic solvent. The extraction was performed starting by both liquid
suspension and freeze-dried nanocapsules and comparing results.
Methanol and dichloromethane have been used respectively for the
extraction of the drug from water suspension and dried material. The
extracted compound could be easily measured by UV–Vis
spectrophotometry after filtration of capsule fragments and inter-
polating results in a calibration curve previously obtained for each
solvent. As the spectrophotometric analysis of bedaquiline in the ex-
traction medium could suffer eventually from some interference of
nanocapsules components, parallel measurements have been carried
out with HPLC separation to further validate results obtained with
spectrophotometric method. Drug loading has been optimized in-
creasing the amount of bedaquiline initially added to the synthesis.
Data referring to DL and EE of the optimization curve are reported in
Fig. S1 of the Supplementary Information.
3.1.2. Lipid nanoparticles
Both anionic and cationic nanoparticles were optimized in terms of
formulation, i.e. weight ratios of core excipients, and drug added during
the preparation (data reported in Table S2 in Supplementary Informa-
tion). The aim was to find the most stable LNPs in storage conditions
with the highest EE. Lipid nanoparticles were prepared by blending
lipid bedaquiline-containing phase and aqueous phase using ultrasonic
process. Non-encapsulated components are separated from LNPs by
dialysis with PBS. A first screening for material optimization has been
made using the LNPs(−) in order to optimize the formulation leading to
the highest EE with a good stability. This optimization has then been
translated to LNPs(+). The loading capacity of LNPs(−) with a core
made of 25% of vegetable oil and 75% of wax (composition already
used in previous studies [27]), has been studied. Different initial
amounts of bedaquiline have been tested: 1%, 3%, 6%, 9% and 12%
(w/w) showing that high LE, 6% and higher, lead to very rapid desta-
bilization (within the 2 first weeks after batch preparation).
In order to improve stability of the LNPs during storage, also the
composition of the lipidic core has been optimized. Three different
ratios of solid lipids in the core have been studied for a six-month
period stability: 0%, 25% and 75%. It clearly appeared that the stability
of LNPs(−) (3% DL) is improved during storage at 4 °C by decreasing
the ratio of solid lipids in the core, and a good stability has been
maintained during six months without any significant EE decrease. The
same kind of behaviour has also been observed with LNPs(+), pre-
senting a DL of 3% (w/w), with identical EE after six months of storage
at 4 °C compared to day 1 after preparation (data reported in
Supplementary Information, Table S2). However, the comparison of DL
and EE showed that the ratio between oil and wax in the core as well as
surface charge of the LNPs did not influence the DL and EE of be-
daquiline. After this screening step, LNPs(−) and LNPs(+) with a DL of
3% (w/w) and a core made of 75% of vegetable oil and 25% of wax
have been chosen as the best candidates for a further study to establish
relationship between biological activity and properties of the surface of
the LNPs.
As it is intended to establish drug release profiles in this work, a
method more suitable than dialysis for EE determination was necessary.
To that end, EE measurements after SEC purification and SPE pur-
ification have been compared to EE directly determined after dialysis of
the batch. It appeared clearly that EE determined directly after dialysis
is higher than what is obtained after further SEC or SPE purification. It
is also important to note that SEC and SPE gave very close values of EE
(Table S1 in Supplementary Information). A possible interpretation is
that the drug loaded on the shell of the LNPs might be desorbed on the
Table 1
Nanocarriers characterization after bedaquiline encapsulation.
Nanocarrier DL, % EE, % Hydrodynamic diameter, nm PDI Z-potential, mV Six-month stability, DL (6 months)/DL (t0),%
CS-NC 28 ± 2 70 ± 7 328 ± 35 0.151 ± 0.027 +26 ± 4 90 ± 10
PEG-CS-NC 25 ± 2 NA 455.6 ± 26 0.204 ± 0.020 −9 ± 2 100 ± 5
LNP(−) 2.8 ± 0.15 93* ± 6 86 ± 1.3 0.148 ± 0.005 −10 ± 1.1 97 ± 5
LNP(+) 2.8 ± 0.15 93* ± 7 83 ± 3.1 0.123 ± 0.009 +28 ± 3 98 ± 4
* EE determined by destruction of LNP and drug extraction in organic solvent after dialysis.
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reverse phase column during SPE extraction or desorbed on the pur-
ification gel when LNP flow through the gel during SEC purification.
SPE purification appeared to be the most suitable for drug release
profiles determination as it is easy to handle, very reproducible and
without any possible contamination between successive samples [22].
3.2. Nanocarriers characterization
Chitosan nanocapsules, with or without PEG outer layer, underwent
to physicochemical characterization to determine their physical char-
acteristics (mainly size and surface potential) and to predict their be-
haviour in biological media.
Bedaquiline-loaded chitosan nanocarriers were characterized in
terms of hydrodynamic diameter and ζ potential. A summary of char-
acterization data, referring to both chitosan and lipid nanocarriers, is
reported in Table 1. Hydrodynamic diameters are reported in terms of
mean diameter. Drug loading and encapsulation efficiency percentages
data have been also summarized in the same table and data referring to
the stability of drug loading over time is also reported (expressed as
ratio between DL measured after a period of 6months from en-
capsulation, with nanocarrier stored at 4 °C, and initial DL).
Hydrodynamic diameter of chitosan nanocapsules resulted to be
significantly bigger than that of LNPs, possibly indicating a different
internal structure of the carrier or a thicker polymeric shell. The dif-
ferences in surface characteristics (charge and composition) did not
affect significantly the size distribution of both chitosan and lipid na-
nocapsules.
The diameter distribution of chitosan nanocapsules, with and
without PEG grafting, is also reported as count percentages corre-
sponding to different diameters in Fig. S2 of Supplementary Informa-
tion together with the same measurement in PBS to demonstrate the
presence of PEG on grafted nanocapsules and its stabilizing effect. In
fact, the aggregation effect observed for CS-NC in phosphate-based
media was completely avoided after covalent linking of PEG on chit-
osan shell, demonstrating that the grafting was successfully achieved.
Hydrodynamic diameter of chitosan nanocapsules was also measured in
NaCl 0.9% to assess their stability. This medium has been taken into
account because it will be interesting for future nebulization studies.
All nanocarriers (both chitosan nanocapsules and lipid nano-
particles) have been found to be slightly polydisperse as PDI values
were all between 0.1 and 0.2. Finally, data obtained from ζ potential
measurements were in good agreement with the differences on nano-
carrier surface in the case of both CS-NCs and LNPs, indicating the
presence of a strong positive charge on nanocarrier surface in the case
of LNPs(+) LNPs and not-grafted CS-NCs.
3.3. Bedaquiline release profiles
The profile of the release of bedaquiline from nanocarriers at 37 °C
was determined at fixed times and media selected on the basis of con-
ditions used in the in vitro assays. Middlebrook 7H9 is the medium used
in M. tuberculosis cultures and RPMI medium was also taken into ac-
count since it is used for infected macrophages cultures, so the beha-
viour of nanocarrier in this medium could be of interest for future in
vitro studies. Release was also measured in the storage media (water
and PBS for CS-NC and LNP respectively) and NaCl 0.9% was used in
Fig. 1. Release profiles of LNPs and CS-NC in different media of biological interest. CS-NC (A), PEG-CS-NC (B), LNPs (+) (C) and LNPs (−) (D).
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the case of CS-NCs in view of the suitability of this carrier for neb-
ulization. Percentages of released bedaquiline at different incubation
times are reported in Fig. 1.
LNPs loaded with bedaquiline were found to be very stable in PBS,
RPMI and Middlebrook 7H9 medium (in all cases less than 10% drug
was released after one week). The release of bedaquiline from CS-NC in
Middlebrook 7H9 broth and in 0.9% NaCl was more significant,
reaching almost 40% after 7 days of incubation. However, release was
found to be quite slow but sustained all along the experiment, with 20%
released after 3 days. On the contrary, NaCl seems to favour a slightly
faster release. In fact, 40% of drug was released after 48 h, although this
value remained unchanged after 7 days. Chitosan nanocapsules grafted
with PEG on their surface showed the same release profile in NaCl and
Middlebrook 7H9 medium. Nevertheless, grafting seems to favour be-
daquiline release in both water and RPMI medium, in which released
percentages reached the same value than in other media after 7 days
incubation. These differences were attributed to the changes in nano-
capsule surface that would strongly affect the interaction of nano-
capsules with proteins and salts contained in Middlebrook 7H9 and
RPMI media. A slightly higher release has been observed in water using
grafted nanocapsules. The difference with non-grafted nanocarriers
could be addressed to the use of borate buffer during the grafting
process. In fact, it could possibly promote some leakage of sulphate ions
from the polymeric network, that could negatively affect its pore size
and so slightly increase the diffusion.
Release in human plasma was also studied in the case of LNPs for
future intravenous injection applications and data are reported in
Fig. 2.
3.4. In vitro antimicrobial activity and cytotoxicity studies
The in vitro antimicrobial activity of the nanocarriers against M.
tuberculosis H37Rv was determined using the well-established REMA
assay [23], and compared to that of free bedaquiline (Table 2).
The MIC of empty carriers was determined as well, to ensure that,
within the range of concentrations used in the assay, the antibacterial
effect was only due to the antimicrobial drug and not to the nanocarrier
itself (data not shown). As shown in Table 2, bedaquiline was still very
active against M. tuberculosis after encapsulation in any of the carriers.
These results were nicely reproduced a minimum of five times, using
different batches of capsules.
As first approach, prior to more accurate, future in vivo toxicity
studies, and as first screening of the effect on human cells of nano-
carriers with encapsulated bedaquiline, cell viability was also de-
termined in in vitro studies using different tests and different cell lines,
to increase the reliability of the results obtained. The cytotoxicity of the
four bedaquiline-loaded nanocarriers was assessed by two different
methods, MTT and NRU, which are the most sensitive assays in de-
tecting cytotoxic events [28].
MTT is the best-known method for determining cellular prolifera-
tion by measuring the conversion of MTT in the mitochondria due to
dehydrogenase activity in the living cells. NRU determines the accu-
mulation of the neutral red dye in the lysosomes of viable, uninjured
cells. The method allows an accurate and reliable quantification of the
viable cells after each treatment[25]. Neutral red uptake assay has been
used for the estimation of cell viability[25]. Both methods were assayed
in three different cell lines: lung epithelial human cells (A549) because
M. tuberculosis infection is located in the lungs, liver epithelial human
cells (HepG2) as the nanoparticles would circulate through the liver,
and human monocytes from peripheral blood (THP-1), chosen because
M. tuberculosis is an intracellular pathogen that resides inside the
macrophages. Results are reported in Table 3.
For the LNPs, the cytotoxicity of the particles was detected only at
very high concentrations, over 1mg/mL. For CS-NCS cytotoxic effect
appears over 0.25mg/mL nanocapsules (70% of survival). However, for
both carriers, tolerated concentrations are in all cases far superior to
those needed to reach the minimum inhibitory concentration of the
drug, i.e. 0.1–0.94 µg/mL and 1–2 µg/mL respectively in the case of CS-
NC and LNP. In other words, none of the bedaquiline-loaded nano-
carriers developed have any cytotoxic effect on A549, HepG2 and THP-
1 cell lines at the concentration needed to kill the bacteria.
3.5. Interaction between bacteria and nanoparticles
As preliminary attempt to study the interaction responsible for the
effect of nanocarriers onM. tuberculosis, a microscopic analysis has been
carried out to evaluate a possible approach or interaction of the parti-
cles with the mycobacterial envelope. Scanning Electron Microscopy
has been used in the case of chitosan nanocapsules and Confocal
Microscopy in the case of lipid nanoparticles due to the sensitiveness of
these carriers to SEM conditions. The aim of the study was to evaluate if
the particles were able to locate next to the bacteria and release the
drug closer to or even inside the bacteria. That would be an important
aspect to take into account for a treatment, since encapsulation would
help to reduce the dose of the drug needed. SEM images of M. tu-
berculosis incubated with chitosan nanoparticles are reported in
Fig. 3B and C, together with a control of the mycobacteria that have not
been incubated with nanocarriers (Fig. 3A).
The carriers were abundantly observed in strict contact with the
bacteria, independently of the presence of PEG on their surface, ap-
parently forming clusters of nanocapsules.
On the other hand, since LNPs do not stand the dehydration needed
to prepare the samples for SEM, another approach was used to visualize
them. LNPs(−) were labelled with the fluorophore DiL (520/570 nm)
and, after incubation with the bacteria, the samples were observed with
the confocal microscope. To help in visualization, a strain of
Mycobacterium bovis BCG (an antivirulent strain used worldwide cur-
rently for vaccination against tuberculosis) expressing GFP was used for
this experiments instead of M. tuberculosis H37Rv. Images are reported
in Fig. 4. Also in this case, the LNPs(−) were found around the bacteria,
but surrounding the bacterial cell in a more homogeneous distribution,
indicating again that this close interaction of nanocarriers with the
bacterial envelope could have possibly an important role in the anti-
bacterial activity observed.
4. Conclusions
Nanocarriers developed in this work were able to encapsulate be-
daquiline, a very effective, although dangerous anti-TB drug, with ex-
cellent efficiency and very good drug loading values and the work
Fig. 2. Release profiles of LNPs in human plasma.
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represents the first bedaquiline encapsulation, at the best of our
knowledge. The aim of the work was to obtain the development and
fundamental physicochemical characterization of this promising na-
nocarriers that would open the way in the future for more in depth
studies to verify the activity of encapsulated bedaquiline against MDR-
TB and investigate the expected decrease in treatment toxicity.
Results obtained were very encouraging, in fact the in vitro anti-
microbial activity of the drug against TB strain H37Rv was maintained
almost unchanged after encapsulation in all the nanocarriers, indicating
that the drug has not been damaged in the process of encapsulation, and
that after encapsulation it is still as effective as the free drug. Moreover
no cytotoxic effect on A549, HepG2 and THP-1 cell lines of bedaquiline-
loaded nanocarriers was observed at the concentration needed to kill
the bacteria.
From the obtained results, it can be concluded that both kinds of
carriers represent very good candidates to be tested for in vivo activity
and toxicity hopefully in view of a safer administration of this drug.
The absence of any burst release of the encapsulated drug in all the
tested nanocarriers, let us hypothesize that the release of the drug could
happen more probably once the material enters in contact with the
bacterial cell. Preliminary microscopy experiments on the interaction of
nanocarriers with bacterial cells indicated the close interaction of na-
nocarriers with the bacteria surface. The proximity of nanocarriers to
bacterial envelope could indicate their possible entrance in the cell or a
delivery of the drug once in contact with the cell wall, taking into ac-
count the lipidic nature of the core of both kind of materials and the
presence of highly hydrophobic mycolic acids in the cell wall of my-
cobacteria.
In conclusion, this work provides an interesting starting point for
the possible future improvement of bedaquiline-based treatments of M.
tuberculosis infections and highlight the need to study more in depth the
interaction of nanomaterials with microbial cell to allow us to obtain
more and more efficient nanocarriers for drug delivery.
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Table 2
MIC values of bedaquiline-loaded nanocarrier.
Nanocarrier MIC
(µg/mL of BQ)
Corresponding concentration of nanocarrier
(µg/mL)





* Range of concentrations taking into account all the batches tested.
Table 3
MTT and NRU results in different cell lines.
Nanocarrier Nanocarrier concentration corresponding to 70% of viability (µg/mL of
nanocarrier)
MTT NRU
A549 HepG2 THP1 A549 HepG2 THP1
CS-NC 100–150 350 150–200 200–250 300 50
PEG-CS-NC 50–100 350 300 150–200 100 ND
LNP(−) 850 > 1000 >1000 >1000 >1000 >1000
LNP(+) 600 >1000 >1000 >1000 250 >1000
Fig. 3. SEM images of M. tuberculosis H37Rv untreated (A1 and A2), incubated with CS-NC (B1 and B2) and with PEG-CS-NC (C1 and C2). The presence of chitosan nanocapsules close to
the bacterial cells is indicated by the arrows.
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